AR089550A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
AR089550A1
AR089550A1 ARP110102793A ARP110102793A AR089550A1 AR 089550 A1 AR089550 A1 AR 089550A1 AR P110102793 A ARP110102793 A AR P110102793A AR P110102793 A ARP110102793 A AR P110102793A AR 089550 A1 AR089550 A1 AR 089550A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
optionally substituted
heterocyclic ring
membered
Prior art date
Application number
ARP110102793A
Other languages
English (en)
Inventor
Peng Bo
Aquila Brian
Kamhi Victor
Pontz Timothy
Carlos Saeh Jamal
Thakur Kumar
Yang Bin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR089550A1 publication Critical patent/AR089550A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide

Abstract

Compuestos, composiciones farmacéuticas y métodos para su preparación. Estos compuestos inhiben la actividad cinasa de ALK y, por lo tanto, se pueden utilizar para tratar el cáncer. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque, o una sal farmacéuticamente aceptable de este, donde: X¹ se selecciona entre los restos de fórmula (2) y (3); X² se selecciona entre -NH- y -N(alquilo C₁₋₄)-; R¹ se selecciona entre H y alquilo C₁₋₄, donde dicho alquilo C₁₋₄ está opcionalmente sustituido con uno o más hidroxi; R² se selecciona entre H, alquilo C₁₋₄, cicloalquilo C₃₋₆ y heterociclilo de 4 a 7 miembros, donde dicho alquilo C₁₋₄ está opcionalmente sustituido con uno o más hidroxi; o R¹ y R² junto con el átomo de nitrógeno al cual están enlazados forman un anillo heterocíclico de 4 a 7 miembros, donde dicho anillo heterocíclico de 4 a 7 miembros está opcionalmente sustituido en carbono con uno o más R²⁰ y donde, si dicho anillo heterocíclico de 4 a 7 miembros contiene un resto -NH-, ese nitrógeno está opcionalmente sustituido con R²⁰*; R³ se selecciona entre H, halo y metilo; R⁴ se selecciona entre halo, -CN, metilo y trifluorometilo; R⁵ se selecciona entre H, halo y alquilo C₁₋₄; R²⁰ en cada caso se selecciona entre halo y alquilo C₁₋₆; R²⁰* se selecciona entre alquilo C₁₋₆, carbociclilo de 3 a 6 miembros, -S(O)R²⁰ᵇ y -S(O)₂R²⁰ᵇ; y R²⁰ᵇ en cada caso se selecciona independientemente entre alquilo C₁₋₆ y carbociclilo de 3 a 6 miembros.
ARP110102793A 2010-08-02 2011-08-02 Compuestos quimicos AR089550A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36991710P 2010-08-02 2010-08-02
US37205510P 2010-08-09 2010-08-09
US39094410P 2010-10-07 2010-10-07

Publications (1)

Publication Number Publication Date
AR089550A1 true AR089550A1 (es) 2014-09-03

Family

ID=45527326

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102793A AR089550A1 (es) 2010-08-02 2011-08-02 Compuestos quimicos

Country Status (14)

Country Link
US (1) US8461170B2 (es)
EP (1) EP2601186A2 (es)
JP (1) JP2013534221A (es)
KR (1) KR20130096241A (es)
CN (1) CN103153982A (es)
AR (1) AR089550A1 (es)
AU (1) AU2011287386A1 (es)
BR (1) BR112013002587A2 (es)
CA (1) CA2805827A1 (es)
MX (1) MX2013001361A (es)
RU (1) RU2013109132A (es)
TW (1) TW201219383A (es)
UY (1) UY33539A (es)
WO (1) WO2012017239A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103702990B (zh) 2011-07-27 2015-09-09 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN102899882B (zh) * 2012-11-07 2014-08-06 西南大学 超亲水涤纶织物的磷酸制备方法
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CN105085550B (zh) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 一类alk激酶抑制剂及其制备方法
MA40240B1 (fr) * 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
AU2015407300B2 (en) * 2015-08-31 2019-06-20 Wuxi Shuangliang Biotechnology Co., Ltd. 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
CN106810553B (zh) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3-(4,5-取代氨基嘧啶)苯基衍生物及其应用
BR112018074232A2 (pt) 2016-05-26 2019-03-06 Zeno Royalties & Milestones, LLC compostos inibidores de egfr
MX2019008808A (es) * 2017-01-26 2019-09-16 Hanmi Pharma Co Ltd Compuesto de pirimidina y su uso farmaceutico.
WO2019019043A1 (zh) * 2017-07-26 2019-01-31 鼎科医疗技术（苏州）有限公司 一种表面液化药物涂层球囊
CA3096790C (en) * 2018-04-09 2024-03-19 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途
CN116763792B (zh) * 2023-06-19 2024-03-12 西安国际医学中心医院 Hg-14-10-04在制备治疗食管鳞癌的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
US20080312211A1 (en) 2005-12-23 2008-12-18 Astrazeneca Ab Antibacterial Pyrrolopyridines, Pyrrolopyrimidines and Pyrroloazepines-154
CA2659582A1 (en) * 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
CN101932580B (zh) 2007-06-01 2013-05-22 葛兰素史密丝克莱恩有限责任公司 咪唑并吡啶激酶抑制剂
EA201000341A1 (ru) 2007-08-23 2010-10-29 Астразенека Аб 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
TW201022262A (en) * 2008-10-29 2010-06-16 Astrazeneca Ab Novel compounds 515

Also Published As

Publication number Publication date
KR20130096241A (ko) 2013-08-29
WO2012017239A2 (en) 2012-02-09
RU2013109132A (ru) 2014-09-10
US8461170B2 (en) 2013-06-11
MX2013001361A (es) 2013-05-17
UY33539A (es) 2012-02-29
CA2805827A1 (en) 2012-02-09
AU2011287386A1 (en) 2013-03-07
BR112013002587A2 (pt) 2019-09-24
JP2013534221A (ja) 2013-09-02
EP2601186A2 (en) 2013-06-12
WO2012017239A3 (en) 2012-04-05
TW201219383A (en) 2012-05-16
US20120028924A1 (en) 2012-02-02
CN103153982A (zh) 2013-06-12

Similar Documents

Publication Publication Date Title
AR089550A1 (es) Compuestos quimicos
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR112834A1 (es) Derivados de rapamicina
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
CU20160030A7 (es) Compuestos éteres de arilo yútiles para tratar cancer de célula renal
AR105459A1 (es) Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR113929A1 (es) Compuestos heterocíclicos
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
BR112015018509A2 (pt) compostos de imidazo piridina
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR091781A1 (es) Antagonistas del receptor de 5-ht3
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
AR093057A1 (es) Inhibidores de la syk
AR091773A1 (es) Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal